

The Economic and Capacity Impact of Time Saved in the Operating Theatre Performing Holmium Laser Enucleation of the Prostate with MOSESTM Technology vs Standard Technology

Bruno L, Demaire C, Sfeir J, Woodward E.

based on ISPOR Europe Poster¹, presented on November 8th 2022 in Vienna, accessible <u>HERE</u>

OBJECTIVE

To estimate time savings in the operating room and the potential economic and capacity impacts, comparing standard vs. MOSESTM technology for Holmium Laser Enucleation of the Prostate (MoLEP vs. HoLEP) in key European countries.¹

BACKGROUND

A recent meta analysis demonstrated that **using MOSESTM technology for HoLEP** was associated with a **statistically reduced operative time.**¹ Reducing time in the operating room (OR) is an important lever for hospitals to optimize their operational efficiency, thus optimizing their costs.²

Gauhar et al.¹ found:


No. of patients	Standard technology	MOSES™ technology	Time difference
included in the OR time analysis	pooled operating time per HoLEP case*	pooled operating time per HoLEP case*	absolute & in percent
381	70.62 min	54.55 min	-16.07 min -22.75%

* Calculated from the pooled Meta Analysis results²

METHODS

An Illustrative Health Economic Model was developed to extrapolate the per-procedure time savings on to a range of potential annual procedure volumes, assuming a 100% switch to MoLEP.

The model evaluated 2 ways to utilise the time savings realizable with MoLEP vs. HoLEP:1



Chapman Jr WC et al.. Time is money: Can punctuality decrease operating theatre cost? J Am Coll Surg. 2020, 230(2):182 189
Gauhar V, et al. Does MOSES Technology enhance the efficiency and outcomes of standard holmium laser enucleation of the prostate? Results of a systematic review and meta analysis of comparative studies. Eur Urol Focus. 2022.

5. BSC data on file

* based on a Netherlands cost analysis


^{4.} Patel S et al. Understanding the costs of surgery: A bottom-up cost analysis of both a hybrid operating room and conventional operating room. Int J Health Policy Manag 2022, 11(3), 299-307



KEY RESULTS

The potential economic impact of MOSESTM technology varies greatly, depending on procedure volume and local reimbursement tariffs for HoLEP procedures. Hospitals with greater volumes and tariffs are likely to benefit the most from time saved in the OR.¹

5 MoLEP procedure times are equivalent to 4 HoLEP procedure times ¹



Scenario 3

- The most nonconservative scenario resulted in a potential increase of annual procedure volume of 22%
- The potential economic impact ranged 13,717 \in in an Italian hospital perfoming 50 HoLEPs/year¹ to 280,547€ in a German hospital performing 400 HoLEPs/year.⁵




Figure 1: Scenario 3, illustration assumes 80% of time saved feeds into the performance of additional procedures and 20% of time is used to save OR costs. of time used to close the OR earlier

of time used to perform additional procedures

CONCLUSION

Using MoLEP vs. standard HoLEP may help hospitals save sufficient time in the OR to increase their procedure volume and ultimately incur additional revenue. Aspects of operative efficiency and workflow should be considered for the adoption of Medical Technologies.¹



For more information on the ISPOR Europe Poster presentation on ,The Economic and Capacity Impact of Time Saved in the Operating Theatre Performing Holmium Laser Enucleation of the Prostate with Moses™ Technology vs Standard Technology', scan the QR-code or click <u>HERE</u> to find the published Abstract and Poster-presentation



For information purposes only. The content of this article/publication is under the sole responsibility of its author/publisher and does not represent the opinion of BSC

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Boston Scientific acquired the global surgical business of Lumenis Ltd. Some registered names of products manufactured and sold by Boston Scientific may contain the term "Lumenis." Lumenis is a registered trademark of Lumenis Be. This material not intended for use in France. 2023

Copyright © Boston Scientific Corporation or its affiliates. All rights reserved.

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved. DINURO2350EA

www.bostonscientific.eu